Candid inks three T cell engager deals; PepGen trial put on holdnews2024-12-16T16:20:50+00:00December 16th, 2024|Endpoints News|
Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax’s $50M milestonenews2024-12-13T15:51:05+00:00December 13th, 2024|Endpoints News|
Elevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego sitenews2024-12-12T15:49:24+00:00December 12th, 2024|Endpoints News|
BenevolentAI restructures; Cimeio, Kyowa ink cell therapy dealnews2024-12-11T15:50:22+00:00December 11th, 2024|Endpoints News|
CervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drugnews2024-12-10T14:44:20+00:00December 10th, 2024|Endpoints News|
Enanta’s mid-stage win in pediatric RSV; Carisma to lay off 34% of staffnews2024-12-09T15:05:13+00:00December 9th, 2024|Endpoints News|
Teva to divest business venture in Japan; Layoffs at Rome Therapeutics news2024-12-06T15:34:11+00:00December 6th, 2024|Endpoints News|
UK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2news2024-12-05T15:51:18+00:00December 5th, 2024|Endpoints News|
AstraZeneca’s new EVP of international amid China investigation; Janux’s $300M offeringnews2024-12-04T16:15:44+00:00December 4th, 2024|Endpoints News|
BMS inks deal with AI Proteins; Terns’ early-stage leukemia datanews2024-12-03T15:25:55+00:00December 3rd, 2024|Endpoints News|
